# Surgical Management of Locally Advanced Lung Cancer

## Overview

Locally advanced NSCLC encompasses T3-T4 and/or N2 disease (stage IIIA and select IIIB). These cases require multimodal therapy with induction systemic therapy followed by surgical resection. Extended resections involve removal of the tumor along with invaded adjacent structures. Careful patient selection through a multidisciplinary tumor board is essential, and the goal is complete (R0) resection with negative margins.

## Sleeve Lobectomy

### Indications

Sleeve lobectomy is indicated for centrally located tumors involving the lobar bronchus or extending to the mainstem bronchus. It serves as an alternative to pneumonectomy with preservation of functional lung parenchyma and has demonstrated superior outcomes compared to pneumonectomy in most series, with lower morbidity and mortality and equivalent oncologic results.

### Technique

The involved lobe is resected along with a segment of the mainstem bronchus, and airway continuity is restored with an end-to-end bronchial anastomosis. The anastomosis is constructed with single interrupted absorbable sutures (such as 4-0 PDS or Vicryl), suturing the membranous portion first and completing the cartilaginous portion. When there is a size mismatch, the smaller bronchus is telescoped into the larger one. The anastomosis is buttressed with a pedicled intercostal muscle flap, pericardial fat pad, or pleural flap. Bronchoscopy confirms anastomotic patency and alignment.

### Vascular Sleeve

When the tumor invades the pulmonary artery, concomitant resection and reconstruction of the vessel is performed. Options include tangential resection with primary repair, patch angioplasty, or sleeve resection with end-to-end anastomosis. A combined bronchial plus vascular sleeve ("double sleeve") addresses complex central tumors. The technical complexity is higher but avoids pneumonectomy.

### Outcomes

Operative mortality for sleeve lobectomy is 2-4% (compared to 5-10% for pneumonectomy). Five-year survival is 40-50% for N0/N1 disease. Anastomotic complications include stricture (3-5%) and dehiscence (1-2%).

<image>Sleeve lobectomy technique showing bronchial resection margins, end-to-end anastomosis with interrupted sutures, and intercostal muscle flap buttress</image>

## Pneumonectomy

### Indications

Pneumonectomy is reserved for central tumors not amenable to sleeve resection, tumors crossing the fissure involving multiple lobes, and extensive hilar lymphadenopathy encasing the mainstem bronchus or pulmonary artery.

### Sleeve Lobectomy vs. Pneumonectomy

| Feature | Sleeve Lobectomy | Pneumonectomy |
|---------|-----------------|---------------|
| Operative mortality | 2-4% | 5-10% (R: 8-12%, L: 5-7%) |
| Lung preservation | Yes (preserves distal lobes) | No |
| 5-Year survival (N0-N1) | 40-50% | 40-50% (equivalent) |
| Post-induction mortality | Acceptable | R pneumonectomy: 20-25% |
| Quality of life | Better | Worse |
| Indication | Central tumors involving lobar bronchus | Central tumors not amenable to sleeve |

### Right vs. Left Pneumonectomy

**Right pneumonectomy** carries higher mortality (8-12%) due to the greater loss of functional lung (55% of total). **Left pneumonectomy** has lower mortality (5-7%) with less physiologic impact. Right pneumonectomy after induction chemoradiation carries the highest risk, with mortality reaching 20-25%.

### Technique

The pulmonary artery, superior and inferior pulmonary veins, and mainstem bronchus are individually ligated. The bronchial stump is closed with a stapler or hand-sewn interrupted sutures and buttressed with a pericardial fat pad, intercostal muscle, or pleural flap. No chest tube or only balanced drainage is used to allow gradual mediastinal shift.

### Postoperative Considerations

**Post-pneumonectomy pulmonary edema** is a potentially fatal complication (2-5%); prevention involves restricting IV fluids, targeting euvolemia or slight negative balance, and avoiding excessive crystalloid intraoperatively. **Bronchopleural fistula** is the most feared complication (2-5% overall, higher on the right), presenting with acute dyspnea, subcutaneous emphysema, fever, and cough productive of serosanguinous fluid; management includes drainage, re-thoracotomy with stump revision, and muscle flap closure. **Postpneumonectomy syndrome** — mediastinal shift causing airway compression — is rare and more common in children and young adults. **Cardiac herniation** is rare but life-threatening if the pericardium is opened and not repaired.

## Chest Wall Resection

### Indications

Chest wall resection is indicated for T3 tumors with invasion of the ribs, intercostal muscles, or soft tissue. En bloc resection of the tumor with the involved chest wall is performed to achieve R0 margins. Preoperative CT and MRI assess the depth of invasion.

### Technique

An en bloc lobectomy with full-thickness chest wall resection is performed, maintaining a minimum 2 cm bony margin from the tumor and typically including 1-2 ribs above and below the involved rib(s). Reconstruction depends on the defect size and location: defects less than 5 cm or in the posterior/subscapular area may not need reconstruction, while larger defects require prosthetic mesh (Gore-Tex, Prolene), methyl methacrylate sandwich, or titanium plates. Muscle flap coverage (latissimus dorsi, serratus anterior, pectoralis) provides soft tissue closure.

### Outcomes

Complete resection with negative margins achieves a 5-year survival of 40-50%, while incomplete resection (R1/R2) drops to less than 20%. The depth of invasion is the primary prognostic factor, not the number of ribs resected.

<image>En bloc chest wall resection with lobectomy showing the extent of rib resection, prosthetic mesh reconstruction, and muscle flap coverage</image>

## Superior Sulcus (Pancoast) Tumors

### Definition and Presentation

Superior sulcus tumors arise at the lung apex and involve thoracic inlet structures. The classic **Pancoast syndrome** includes shoulder and arm pain, Horner syndrome (ptosis, miosis, anhidrosis), and hand weakness from C8-T1 nerve root involvement. These tumors may invade the brachial plexus, subclavian vessels, stellate ganglion, vertebral bodies, and the first rib.

### Workup

MRI of the thoracic inlet is essential for assessing brachial plexus, subclavian vessel, and vertebral body involvement. PET-CT provides staging. Mediastinal staging (EBUS or mediastinoscopy) is critical because N2 disease is a relative contraindication to surgery. Neurovascular assessment by a multidisciplinary team is necessary.

### Treatment Approach

**Trimodality therapy** — induction concurrent chemoradiation followed by surgical resection — is the standard approach based on SWOG 8805/Intergroup 0160. Induction chemoradiation uses cisplatin plus etoposide with 45 Gy of concurrent radiation therapy. Restaging is performed after induction therapy, and surgical resection follows 3-5 weeks after completing induction. The pathologic complete response rate is approximately 30%, and 5-year survival with complete resection is 40-50%.

### Superior Sulcus Tumor Surgical Approaches

| Approach | Indication | Key Feature |
|----------|-----------|-------------|
| Anterior (Dartevelle/transmanubrial) | Anterior tumors involving subclavian vessels | Transcervical incision with partial/complete manubriectomy |
| Posterior (Paulson/Shaw-Paulson) | Posterior tumors invading ribs and vertebral bodies | Posterolateral thoracotomy with extension |
| Combined anterior-posterior | Extensive tumors requiring both approaches | Addresses anterior and posterior structures |

### Surgical Approaches

The **anterior (Dartevelle/transmanubrial)** approach is used for tumors involving the subclavian vessels anteriorly, using a transcervical incision with partial or complete manubriectomy to allow subclavian vessel control and reconstruction. The **posterior (Paulson/Shaw-Paulson)** approach — a classic posterolateral thoracotomy with extension — is the standard for posterior tumors invading ribs and vertebral bodies. A **combined anterior-posterior** approach addresses extensive tumors requiring both approaches. En bloc resection includes involved structures: ribs (T1-T3), stellate ganglion, lower trunk of the brachial plexus, subclavian artery (reconstructed with graft), and vertebral body (with spinal stabilization).

### Contraindications to Surgery

Surgery is contraindicated with N2 lymph node disease, vertebral body invasion beyond one level, brachial plexus invasion above C8 (involvement of C7 and above leads to a non-functional arm), and subclavian artery encasement (relative — some centers still resect and reconstruct).

<image>MRI of superior sulcus tumor demonstrating relationship to brachial plexus, subclavian vessels, and vertebral body with planned surgical approach overlay</image>

## Carinal Resection and Reconstruction

Carinal resection is a rare procedure for tumors involving the carina or extending from the mainstem bronchus to the trachea. It represents the highest complexity airway reconstruction. Techniques include carinal pneumonectomy and carinal resection with reconstruction. Meticulous airway management with cross-field ventilation is required. Release maneuvers (suprahyoid, pericardial, hilar) reduce anastomotic tension. Mortality remains 10-15% even in experienced centers.

## N2 Disease: Surgical Role

### Patient Selection

Single-station, non-bulky N2 disease identifies the best surgical candidates after induction therapy. Multi-station or bulky N2 disease is generally treated with definitive chemoradiation. Restaging after induction therapy is mandatory. Persistent N2 disease after induction is a poor prognostic sign, and surgery in this setting is of uncertain benefit.

### Induction Therapy for N2

Neoadjuvant chemotherapy plus immunotherapy is the current preferred approach. Neoadjuvant concurrent chemoradiation represents the traditional approach. Assessment of mediastinal clearance requires repeat EBUS or mediastinoscopy. Downstaging to N0-N1 is associated with significantly better survival.

## Clinical Pearls

Sleeve lobectomy should always be considered before pneumonectomy because it achieves equivalent oncologic outcomes with lower mortality and better quality of life. Right pneumonectomy after induction therapy carries prohibitive mortality in many series, and alternatives should be sought. For Pancoast tumors, MRI of the thoracic inlet is mandatory — CT alone is insufficient to assess neurovascular invasion. Complete (R0) resection is the most important prognostic factor in locally advanced NSCLC, and if R0 cannot be achieved, surgery may not be beneficial. Bronchial stump buttressing with a vascularized tissue flap reduces bronchopleural fistula risk, especially after induction therapy. Post-pneumonectomy pulmonary edema is prevented, not treated — restrictive fluid management is critical from induction through the first 48 hours.

## References

- Deslauriers J et al. "Sleeve lobectomy versus pneumonectomy for lung cancer." *J Thorac Cardiovasc Surg*. 2004.
- Rusch VW et al. "Induction chemoradiation and surgical resection for superior sulcus tumors (SWOG 8805/Intergroup 0160)." *J Thorac Cardiovasc Surg*. 2001.
- Albain KS et al. "Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer (INT 0139)." *Lancet*. 2009.
- Dartevelle PG et al. "Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet." *J Thorac Cardiovasc Surg*. 1993.
- NCCN Clinical Practice Guidelines: Non-Small Cell Lung Cancer. Version 2024.